Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukem... ( NEW BRUNSWICK N.J. June 27 2011 /- Re...)

Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects

Date:6/27/2011

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of Leukothera^TM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining Leukothera^TM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone. Leukothera^TM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said. "The biological mechanism of Leukothera^TM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey. The company has exclusively licensed the rights to develop Leukothera^TMas a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

"We provided early seed funding to Actinobac because we are convinced that
'/>"/>

SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
3. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
4. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
5. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
6. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. In a New Audio Interview at SmallCapVoice.com, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Nektar Therapeutics (Nasdaq: ... a human abuse liability (HAL) study for NKTR-181, ... entry into the brain. This slow rate of entry is ... abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and "feeling ...

(Date:6/19/2013)... /PRNewswire-iReach/ -- Today leading web researchers Change Sciences Group ... web sites for usability, engagement, and conversion. The rankings ... which compares how people experience sites with competitors and ... The top three performers are easier to use, more ... performers have usability problems, lack aspects of design that ...

(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...

[0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall [0] MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution

... to be held on Wednesday, August 6, 2008 at 8:00 ... ... 5 Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety ... the,Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles.,Each study, conducted ...

... WHIPPANY, N.J., Aug. 5 Nexgen Spine, a ... treatment of,degenerative disc disease, announced today that it ... Lumbar Artificial Disc in the European,Union., "We ... has,received CE mark approval," said Alastair Clemow, Ph.D., ...

Cached Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5 Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2

Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc

(Date:6/20/2013)... June 20, 2013 Footwear etc. is pleased ... USA , and has received many new styles and colors ... models, and models never before introduced in the U.S. The ... loyal following of MBT customers. , MBT shoes feature a ... on sand. This sole also provides outstanding shock absorption, and ...

(Date:6/20/2013)... June 20, 2013 TASC, a ... announced a new service to deal with funding ... the Patient Protection & Affordable Care Act (PPACA), ... health outcomes, clinical effectiveness, and appropriateness" of different ... and conduct its own, with funding in part ...

(Date:6/20/2013)... David Icke, the highly visible alternative researcher and ... , Fresh from the Bilderburg fringe festival and the ... to launch ‘The Peoples Voice’ TV and Radio station by ... opportunity for journalists to cover the stories and investigations that ... globe. , Because this station is for the people, ...

(Date:6/20/2013)... Sydney, Australia (PRWEB) June 20, 2013 ... , research was presented recently, that can show similarities ... food. This could explain the current global obesity ... be addicted to food just as one can be ... Neuroscience and Applied Cognitive Science at the University of ...

(Date:6/20/2013)... 2013 HIPAA One aims ... through a HIPAA Security Risk Analysis using the simplest ... extends the reach of all the HIPAA programs by ... Privacy Officers, security professionals, and members of the Healthcare ... policies and procedures. The new Web site features ...

Breaking Medicine News(10 mins):Health News:Footwear etc. Announces New MBT Shoes for Spring/Summer 2 Health News:TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans 2 Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2 Health News:Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution 2

[0] Footwear etc. Announces New MBT Shoes for Spring/Summer [0] TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans [0] David Icke to Launch Global TV and Radio Station Called The People's Voice [0] Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic [0] Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution

... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...

... May 6 Funds in the FY 2010 budget aimed ... to improve access to outpatient physical therapy services for Medicare ... Therapy Association (APTA). S.Con.Res.13 ... 2009-FY 2014, was passed April 29 by the House of ...

... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...

... Team Finance LLC (the "Company"), today announced results for the ... uncollectibles ("revenue less provision") in the first quarter of 2009 ... first quarter of 2008. Same contract revenue less provision ... million in the same period a year ago. In ...

... bare-metal version, studies show , , WEDNESDAY, May 6 ... stents are less likely to become blocked again than ... and heart attacks is virtually identical between the two ... show. , The Swedish results eliminate concerns raised by ...

... of those hospitalized in U.S. is 15, CDC says , , ... of U.S. cases of swine flu continue to be mild, ... be atypically young, federal health officials said Wednesday. , The ... which is younger than occurs with regular seasonal flu, Dr. ...

U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility Funds in 2010 Budget Could Increase Access to Care for Medicare Beneficiaries Bono Mack, Lowey Introduce Bill To Improve the Health of Youth Team Finance LLC Announces First Quarter 2009 Results Drug-Coated Stents Better at Keeping Arteries Open Younger Age of More Severe Swine Flu Cases Worries Experts

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Hepatitis C Virus RNA Qualitative PCR Hepatitis C Virus Antibody with Reflex to Supplemental RIBA Hepatitis C Virus Antibody Hepatitis C Virus Antibody (RIBA), Supplemental